<div class="p4l_caption"><div class="p4l_captionTitle"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4253425/" ref="ordinalpos=250&amp;ncbi_uid=6900318&amp;link_uid=PMC4253425" image-link="/pmc/articles/PMC4253425/figure/F6/" class="imagepopup">Figure 6. Inhibition of ALK <span class="highlight" style="background-color:">signaling</span> <span class="highlight" style="background-color:">pathway</span> by Crizotinib in PANC-1 cells.  From: Crizotinib Exhibits Antitumor Activity by Targeting ALK <span class="highlight" style="background-color:">Signaling</span> not c-MET in Pancreatic Cancer. </a></div><br /><div class="p4l_captionBody"><b>(A)</b> The ability of Crizotinib to target ALK signaling pathway was analyzed by Phospho-Kinase array after PANC-1 cells were treated with Crizotinib (5 μM) for 2 hr (*p &lt; 0.05 and ** p &lt;0.01, compared to control). <b>(B)</b> The expression of p-STAT3, p-AKT, and p-ERK were measured by western blotting after PANC-1 cells were treated with Crizotinib at the indicated doses (0-20 μM) for 2 hr.</div></div>